Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
489
datasets available to search
ShareScore release 0.9.0
Dataset results
489 results for “appendages”
The brittle star genome illuminates the genetic basis of animal appendage regeneration
GEO Series GSE246675. Amphiura filiformis. 28 samples. Type: Expression profiling by high throughput sequencing.
Developmental defects in ectodermal appendages caused by missense mutation in edaradd gene in the nfr mangrove killifish, Kryptolebias marmoratus
GEO Series GSE273026. Kryptolebias marmoratus. 12 samples. Type: Expression profiling by high throughput sequencing.
Fig. 6 Argia pocomana Calvert. Male caudal appendages. a in Argia mayi, a new species from México (Zygoptera: Coenagrionidae)
Fig. 6 Argia pocomana Calvert. Male caudal appendages. a) Mediodorsal, b) lateral, c) dorsal views
Dataset related to article "Left atrial appendage closure with the II generation Ultraseal device: An international registry. The LIGATE study "
<p>This record contains raw data related to article "Left atrial appendage closure with the II generation Ultraseal device: An international registry. The LIGATE study "</p> <p>Abstract</p> <p><strong>Objectives: </strong> To assess feasibility and safety of second-generation left atrial appendage closure (LAAC) Ultraseal device in patients with nonvalvular atrial fibrillation (NVAF).</p> <p><strong>Background: </strong> LAAC with first-generation Ultraseal device (Cardia, Eagan, Minnesota) has been shown to be a feasible therapeutic option in patients with NVAF. However, there is a paucity of data regarding the novel second-generation Ultraseal device.</p> <p><strong>Methods: </strong> All patients with NVAF undergoing second-generation Ultraseal device implantation between February 2018 and September 2020 were included in a multicenter international registry. Periprocedural and post-discharge events were collected through 6-month follow-up. Co-primary efficacy endpoints were device success and technical success while primary safety endpoint was in-hospital major adverse event (MAE) occurrence.</p> <p><strong>Results: </strong> A total of 52 patients were included: mean age 75 ± 8, 30.8% women, mean HAS-BLED 3 ± 1. The device was successfully implanted in all patients. Technical success was achieved in 50 patients (96.1%). In-hospital MAEs occurred in three patients (5.8%). The incidence of 6-month all-cause death and major bleeding was 11.6% and 2.1%, respectively. No strokes, transient ischemic attacks, systemic embolisms, or device embolization were reported after discharge.</p> <p><strong>Conclusions: </strong> Second-generation Ultraseal device implantation was associated with high success rates and a low incidence of peri-procedural complications. Larger studies with longer follow-up are warranted to further evaluate the safety and the efficacy of this device, especially at long-term follow-up.</p>
Comparison of atrial appendage tissues of patients with Valvular Heart Disease and patients with Valvular Heart Disease-Atrial Fibrillation
GEO Series GSE113013. Homo sapiens. 10 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
Rewiring of gene interactions during development of serially homologous appendages in male and female Drosophila
GEO Series GSE279524. Drosophila melanogaster. 1 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Array-based genome-wide transcriptome analysis of the left atrial appendage for the difference between SR maintenance group and AF recurrence group
GEO Series GSE176166. Homo sapiens. 7 samples. Type: Expression profiling by array.
Diagnosis of left atrial appendage thrombus in patients with atrial fibrillation: delayed contrast-enhanced cardiac CT
<p>Dataset from the article Spagnolo P, Giglio M, Di Marco D, Cannaò PM, Agricola E, Della Bella PE, Monti CB, Sardanelli F. Diagnosis of left atrial appendage thrombus in patients with atrial fibrillation: delayed contrast-enhanced cardiac CT. Eur Radiol. 2021 Mar;31(3):1236-1244. doi: 10.1007/s00330-020-07172-2. Epub 2020 Sep 4. PMID: 32886202; PMCID: PMC7880950.</p> <p><strong>Abstract</strong></p> <p><strong>Objectives: </strong>The current reference standard for diagnosing LAA thrombi is transesophageal echocardiography (TEE), a semi-invasive technique. We aimed to devise an optimal protocol for cardiac computed tomography (CCT) in diagnosing left atrial appendage (LAA) thrombus in patients with atrial fibrillation (AF), using TEE as reference standard.</p> <p><strong>Methods: </strong>Two hundred sixty consecutive patients referred for radiofrequency ablation for AF were prospectively enrolled. All patients underwent CCT and TEE within 2 hours. The CCT protocol included one standard angiographic phase and three delayed acquisitions at 1-, 3-, and 6-min after contrast injection. Thrombi were defined as persisting defects at 6-min delayed acquisition.</p> <p><strong>Results: </strong>TEE demonstrated spontaneous contrast in 52 (20%) patients and thrombus in 10 (4%). In 63 patients (24%), CCT demonstrated LAA early filling defects at angiographic phase. Among them, 15 (6%) had a persistent defect at 1-min, 12 (5%) at 3-min, and 10 (4%) at 6-min. All 10 thrombi diagnosed on TEE were correctly identified by delayed CCT, without any false positives. For all phases, sensitivity and negative predictive were 100%. Specificity increased from 79% for the angiographic phase to 100% at 6-min. Positive predictive value increased from 16% to 100%. Estimated radiation exposure was 2.08 ± 0.76 mSv (mean ± standard deviation) for the angiographic phase and 0.45 ± 0.23 mSv for each delayed phase.</p> <p><strong>Conclusion: </strong>A CCT protocol adding a 6-min delayed phase to the angiographic phase can be considered optimized for the diagnosis of LAA thrombi, with a low radiation dose.</p>
Mechanical concordance between left atrium and left atrial appendage in nonvalvular atrial fibrillation: can it be exploited to avoid transesophageal echocardiography prior to electrical cardioversion during Covid‑19 pandemic?
<p>Transesophageal echocardiography (TEE) is the gold standard for assessing left atrial appendage (LAA) mechanic and throm-<br> bosis (LAAT); however, TEE is a high-risk procedure for viral transmission during coronavirus disease 2019 (COVID-19) <br> pandemic. We investigated whether deformation indices of left atrium (LA) at transthoracic echocardiography (TTE) correlate <br> with those of LAA assessed by TEE in nonvalvular atrial fibrillation (NVAF) patients undergoing electrical cardioversion <br> (ECV). Consecutive patients with NVAF of ≥ 48 h or unknown duration, who underwent TEE and TTE at our Institution <br> before ECV were retrospectively investigated. Standard echo-Doppler and LA and LAA myocardial strain and strain rate <br> parameters were analyzed. A total of 115 NVAF patients (71.3 ± 8.1 yr/o, 59.1% men) were included: LAAT was diagnosed <br> in 25 (21.7%) patients. Compared to patients without LAAT, those with LAAT had significantly higher CHA2DS2-VASc <br> Risk score (4.5 ± 1.4 vs. 3.5 ± 1.1, p < 0.001), and lower ejection fraction (46.0 ± 14.8 vs. 57.6 ± 8.6%, p < 0.001). In LAAT <br> patients, global strain of LA (8.7 ± 2.6 vs. 16.3 ± 4.5%, p < 0.001) and LAA (7.0 ± 1.7 vs. 11.7 ± 2.0%, p < 0.001) was sig-<br> nificantly reduced compared to non-LAAT patients. A close relationship between left atrial strain reservoir (LASr) and <br> LAA-global strain was demonstrated (r = 0.81). By univariable analysis, CHA2DS2-VASc Risk Score (OR 2.01, 95%CI <br> 1.34–3.00), NT-proBNP (OR 1.36, 95%CI 1.19–1.54), ejection fraction (OR 0.92, 95%CI 0.88–0.96), E/e’ ratio (OR 2.07, <br> 95%CI 1.51–2.85), and LASr (OR 0.39, 95%CI 0.25–0.62) were strongly associated with LAAT presence at TEE. By mul-<br> tivariable analysis, only LASr (OR 0.40, 95%CI 0.24–0.70) retained statistical significance. ROC curve analysis revealed <br> that an LASr cut-off value ≤ 9.3% had 98.9% sensibility and 100% specificity to identify LAAT by TEE (AUC = 0.98). In <br> patients with NVAF of ≥ 48 h or unknown duration, scheduled to undergo ECV, LA deformation assessment by TTE might <br> substitute invasive measurement of LAA function by TEE, simplifying diagnostic approach and possibly contributing to <br> reduce COVID-19 infection diffusion.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.